- NOX66 delivers idronoxil across blood-brain barrier
- High drug levels achieved
- Promise of ability to boost response rate of brain cancers to standard therapies.
Noxopharm Limited (ASX:NOX) announces that its NOX66 delivery technology successfully delivers high levels of the experimental anti-cancer drug, idronoxil, to the brain.
The blood-brain barrier is a robust barrier that serves to exclude foreign chemicals from accessing brain tissue. While serving a vital protective function to protect the brain from potentially harmful compounds, it also inadvertently prevents many drugs from accessing the brain that are intended to deliver a therapeutic benefit.
For further information please download PDF attached:
Download this document
